Omeros Corporation (OMER)

Market Cap	1.32B +355.4%
Revenue (ttm)	38.42M
Net Income	124.83M
EPS	1.57
Shares Out	72.39M
PE Ratio	12.46
Forward PE	20.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,014,302
Open	18.74
Previous Close	18.59
Day's Range	18.28 - 18.98
52-Week Range	3.94 - 19.65
Beta	2.60
Analysts	Buy
Price Target	33.00 (+80.53%)
Earnings Date	Aug 12, 2026

About OMER

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 175
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER
• Website: https://www.omeros.com

Analyst Summary

According to 3 analysts, the average rating for OMER stock is "Buy." The 12-month stock price target is $33.0, which is an increase of 80.53% from the latest price.

Price Target

$33.0

(80.53% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 12, 2026

Data Sources Report a data error